Researchers cast doubt over benefits of new Alzheimer’s therapies
Lecanemab and donanemab are two of the most recent medicines to treat Alzheimer’s disease.
Biogen
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug
The EU’s Medicines Agency (EMA) rejects market authorisation for early intervention Alzheimer’s treatment Leqembi (lecanemab) due to concerns over side-effects.